Vaxcyte, Inc. (NASDAQ:PCVX) Shares Acquired by Banque Cantonale Vaudoise

Banque Cantonale Vaudoise lifted its holdings in Vaxcyte, Inc. (NASDAQ:PCVX) by 96.7% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,184 shares of the company’s stock after buying an additional 582 shares during the quarter. Banque Cantonale Vaudoise’s holdings in Vaxcyte were worth $81,000 as of its most recent SEC filing.

A number of other institutional investors have also recently modified their holdings of the business. Xponance Inc. boosted its stake in shares of Vaxcyte by 3.0% in the fourth quarter. Xponance Inc. now owns 5,672 shares of the company’s stock valued at $356,000 after buying an additional 163 shares in the last quarter. Ellsworth Advisors LLC boosted its stake in shares of Vaxcyte by 2.6% in the fourth quarter. Ellsworth Advisors LLC now owns 8,060 shares of the company’s stock valued at $506,000 after buying an additional 207 shares in the last quarter. Parallel Advisors LLC boosted its stake in shares of Vaxcyte by 155.3% in the fourth quarter. Parallel Advisors LLC now owns 411 shares of the company’s stock valued at $26,000 after buying an additional 250 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of Vaxcyte by 0.6% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 51,136 shares of the company’s stock valued at $3,211,000 after buying an additional 296 shares in the last quarter. Finally, Principal Financial Group Inc. boosted its stake in shares of Vaxcyte by 1.7% in the fourth quarter. Principal Financial Group Inc. now owns 22,008 shares of the company’s stock valued at $1,382,000 after buying an additional 376 shares in the last quarter. 96.78% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on PCVX. Cantor Fitzgerald restated an “overweight” rating on shares of Vaxcyte in a research note on Thursday, June 20th. Needham & Company LLC reiterated a “buy” rating and set a $95.00 target price on shares of Vaxcyte in a research report on Thursday, May 9th.

Insider Transactions at Vaxcyte

In other news, Director Halley E. Gilbert sold 18,200 shares of the business’s stock in a transaction on Monday, June 3rd. The stock was sold at an average price of $73.00, for a total value of $1,328,600.00. Following the completion of the transaction, the director now directly owns 5,625 shares of the company’s stock, valued at $410,625. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In other news, Director Halley E. Gilbert sold 18,200 shares of the business’s stock in a transaction on Monday, June 3rd. The stock was sold at an average price of $73.00, for a total value of $1,328,600.00. Following the completion of the transaction, the director now directly owns 5,625 shares of the company’s stock, valued at $410,625. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO Grant Pickering sold 15,000 shares of the business’s stock in a transaction on Tuesday, April 23rd. The stock was sold at an average price of $61.92, for a total value of $928,800.00. Following the completion of the transaction, the chief executive officer now directly owns 477,847 shares of the company’s stock, valued at $29,588,286.24. The disclosure for this sale can be found here. Insiders sold a total of 71,483 shares of company stock valued at $4,913,533 over the last three months. 3.10% of the stock is currently owned by insiders.

Vaxcyte Trading Up 1.1 %

PCVX opened at $75.78 on Tuesday. The business’s fifty day moving average is $68.44 and its two-hundred day moving average is $67.49. Vaxcyte, Inc. has a one year low of $44.20 and a one year high of $82.04.

Vaxcyte (NASDAQ:PCVX) last released its quarterly earnings results on Wednesday, May 8th. The company reported ($0.85) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.13) by $0.28. Analysts forecast that Vaxcyte, Inc. will post -3.96 earnings per share for the current fiscal year.

About Vaxcyte

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.